TrustCore Financial Services’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

TrustCore Financial Services’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,000	Closed	-$5K	–	1002
2019 Q4	$5K	Hold	1,000	–	–	﹤0.01%	741
2019 Q3	$5K	Hold	1,000	–	–	﹤0.01%	763
2019 Q2	$6K	Hold	1,000	–	–	﹤0.01%	720
2019 Q1	$5K	Buy	+1,000	New	+$4.53K	﹤0.01%	684
2018 Q4	–	Sell	-1,000	Closed	-$6K	–	852
2018 Q3	$6K	Hold	1,000	–	–	﹤0.01%	652
2018 Q2	$8K	Hold	1,000	–	–	﹤0.01%	612
2018 Q1	$7K	Hold	1,000	–	–	﹤0.01%	559
2017 Q4	$6K	Buy	+1,000	New	+$6.08K	﹤0.01%	564

Other funds holding PGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

TrustCore Financial Services's PGNX Position: Q1 2020 in Review

TrustCore Financial Services sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2020, closing a stake of 1,000 shares — an estimated $5K sold.

TrustCore Financial Services first reported a position in PGNX in Q4 2017 and held it in 8 quarters. The position peaked at $8K in Q2 2018. 129 funds tracked by Wall St. Rank hold PGNX as of Q1 2020.

TrustCore Financial Services reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2020 after selling out during the quarter.
TrustCore Financial Services sold 1,000 Progenics Pharmaceuticals Inc shares in Q1 2020, an estimated $5K.
TrustCore Financial Services first reported a position in Progenics Pharmaceuticals Inc in Q4 2017 and held it in 8 quarters.
TrustCore Financial Services's Progenics Pharmaceuticals Inc position peaked at $8K in Q2 2018.
129 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2020.

Based on TrustCore Financial Services's 13F filing for Q1 2020, filed 7 May 2020.